8-K: Surmodics Exceeds Expectations in Q2, Launches New Thrombectomy Devices and Raises Full Year Guidance

Surmodics reported strong second-quarter results, driven by medical device sales and the launch of two new thrombectomy devices, leading to an increase in full-year financial guidance.

Summary

• Surmodics announced its financial results for the second quarter of fiscal year 2024, ending March 31, 2024.
• Total revenue reached $32.0 million, an 18% increase year-over-year, or 19% excluding SurVeil DCB license fees.
• The Medical Device segment saw a 26% revenue increase, driven by a 40% jump in product sales.
• GAAP net income was $0.2 million, a significant improvement from a net loss of $7.7 million in the same period last year.
• Adjusted EBITDA was $4.8 million, compared to a loss of $1.5 million in the prior year.
• The company launched two new thrombectomy devices, Pounce Venous and Pounce LP, for venous and arterial applications respectively.
• Surmodics has raised its full-year revenue guidance to $122-$124 million and improved its EPS guidance to a loss of $(0.90) to $(0.70) per share.
• The company ended the quarter with $41 million in cash and investments, and generated over $7 million in cash flow from operations.

Sentiment

Score: 8

Explanation: The document conveys a strong positive sentiment due to the company's improved financial performance, successful product launches, and raised guidance. The company's management also expresses confidence in future growth.

Positives

• Surmodics achieved profitability in the second quarter with a GAAP net income of $0.2 million.
• The company experienced strong growth in its Medical Device segment, particularly in product sales.
• The commercial launch of two new thrombectomy devices expands the company's product portfolio.
• Surmodics has improved its full-year financial guidance, indicating confidence in future performance.
• The company generated significant cash flow from operations, strengthening its balance sheet.
• The Pounce Venous Thrombectomy System showed 100% success in a first-in-human study with no device-related adverse events.

Negatives

• In Vitro Diagnostics (IVD) revenue decreased by 5% year-over-year.
• Product gross margin decreased to 60.8% from 62.6% due to increased sales of newer products not yet at scale.
• Total revenue guidance for fiscal 2024 still represents a decrease of (8)% to (6)% compared to fiscal 2023, although this is an improvement on previous guidance.

Risks

• The company's ability to successfully commercialize new products like SurVeil DCB and the Pounce thrombectomy devices is crucial.
• Surmodics relies on third parties for the development, marketing, and sales of products incorporating their technologies.
• Adverse market conditions and supply chain constraints could impact the company's cash flows and operations.
• The company's operating expenses must be effective in generating profitable revenues.
• The company's plan to reduce cash usage may not achieve its objectives or may incur additional costs.

Future Outlook

Surmodics expects continued growth in its core businesses and commercial traction in its vascular interventions portfolio, with the recent introduction of four new products expected to drive strong, sustained revenue performance. The company is focused on facilitating the adoption of these growth catalysts and allocating capital to enhance profitability.

Management Comments

• Gary Maharaj, President and CEO of Surmodics, Inc., stated that the company's strong financial performance exceeded expectations.
• Mr. Maharaj highlighted the impressive pace of execution by the teams in the second quarter.
• He noted that total revenue growth was primarily fueled by product sales growth in the Medical Device segment.
• Mr. Maharaj mentioned the company's focus on controlling expenses, which contributed to net income profitability.
• He expressed excitement about the full commercial launch of the Pounce Venous and Pounce LP products.
• Mr. Maharaj stated that the company is raising its revenue and EPS guidance for the second time this year.
• He believes the company is well-positioned to deliver strong, sustained revenue performance.

Industry Context

This announcement reflects a positive trend in the medical device industry, particularly in the vascular intervention space. The launch of new thrombectomy devices aligns with the growing demand for minimally invasive procedures and advanced technologies for treating vascular conditions. Surmodics' focus on innovation and commercialization positions them well to compete in this market.

Comparison to Industry Standards

• Surmodics' 18% year-over-year revenue growth is strong compared to the average growth rate in the medical device industry, which typically ranges from 5-10%.
• The 40% growth in Medical Device product sales is particularly impressive, indicating strong market acceptance of their products.
• Companies like Boston Scientific and Medtronic, which also operate in the vascular intervention space, have reported varying growth rates, but Surmodics' performance in this quarter is noteworthy.
• The successful launch of the Pounce thrombectomy devices positions Surmodics to compete with other companies offering similar solutions, such as Penumbra and Inari Medical.
• The improvement in profitability, with a shift from a net loss to net income, is a positive sign and indicates effective cost management, which is a key focus for many medical device companies.

Stakeholder Impact

• Shareholders will likely react positively to the improved financial results and raised guidance.
• Employees may be encouraged by the company's success and future prospects.
• Customers will benefit from the availability of new and innovative medical devices.
• Suppliers may see increased demand for their products and services.
• Creditors may have increased confidence in the company's ability to meet its obligations.

Next Steps

• Surmodics will focus on facilitating the adoption of its new products, including the SurVeil DCB and Pounce thrombectomy devices.
• The company will continue to execute against its strategic initiatives and allocate capital to enhance profitability.
• Surmodics will host a live webcast to discuss the second quarter results and host a question-and-answer session.

Key Dates

Keywords

Surmodics, thrombectomy, medical devices, vascular intervention, Pounce, SurVeil DCB, financial results, revenue, EBITDA, net income, guidance, performance coatings, in vitro diagnostics